The xanthine oxidase inhibitor oxypurinol reduces cancer cachexia-induced cardiomyopathy

Jochen Springer, Anika Tschirner, Kai Hartman, Stephan von Haehling, Stefan D Anker, Wolfram Doehner

Research output: Contribution to journalArticle

33 Citations (Scopus)

Abstract

Cachexia is a common complication of cancer and may be responsible for 22% of all cancer-related deaths. The exact cause of death in cancer cachexia patients is unknown. Recently, atrophy of the heart has been described in cancer cachexia animal models, which resulted in impaired cardiac function and is likely to contribute to mortality. In cancer patients hyperuricaemia independent of tumour lysis syndrome is often associated with a worse prognosis. Xanthine oxidase (XO) metabolizes purines to uric acid and its inhibition has been shown to improve clinical outcome in patients with chronic heart failure.
Original languageEnglish
Pages (from-to)3527-3531
Number of pages5
JournalInternational Journal of Cardiology
Volume168
Issue number4
DOIs
Publication statusPublished - 9 Oct 2013

Cite this